These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38813034)

  • 1. CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients.
    Boral B; Tuncer İ; Kibar F; Çetiner S; Badak SÖ; Salman E; Koç E; Erken E; Yaman A
    Turk J Med Sci; 2023; 53(5):1075-1083. PubMed ID: 38813034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis.
    Peres RS; Liew FY; Talbot J; Carregaro V; Oliveira RD; Almeida SL; França RF; Donate PB; Pinto LG; Ferreira FI; Costa DL; Demarque DP; Gouvea DR; Lopes NP; Queiroz RH; Silva JS; Figueiredo F; Alves-Filho JC; Cunha TM; Ferreira SH; Louzada-Junior P; Cunha FQ
    Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2509-14. PubMed ID: 25675517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis.
    Peres RS; Donate PB; Talbot J; Cecilio NT; Lobo PR; Machado CC; Lima KWA; Oliveira RD; Carregaro V; Nakaya HI; Cunha TM; Alves-Filho JC; Liew FY; Louzada-Junior P; Cunha FQ
    J Autoimmun; 2018 Jun; 90():49-58. PubMed ID: 29426578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.
    Zacca ER; Amezcua Vesely MC; Ferrero PV; Acosta CDV; Ponce NE; Bossio SN; Mussano E; Onetti L; Cadile I; Acosta Rodríguez EV; Montes CL; Gruppi A
    J Mol Biol; 2021 Jan; 433(1):166687. PubMed ID: 33098857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a Type 2-Polarized T Cell Phenotype With Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
    Slauenwhite D; McAlpine SM; Hanly JG; Malik A; Haidl ID; Marshall JS; Issekutz TB
    Arthritis Rheumatol; 2020 Jul; 72(7):1091-1102. PubMed ID: 32039570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
    Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
    Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response.
    Ortiz MA; Diaz-Torné C; De Agustin JJ; Estrada P; Reina D; Hernandez MV; Sang H; Zamora C; Cantó E; Corominas H; Vidal S
    Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38275742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for
    Spiliopoulou A; Colombo M; Plant D; Nair N; Cui J; Coenen MJ; Ikari K; Yamanaka H; Saevarsdottir S; Padyukov L; Bridges SL; Kimberly RP; Okada Y; van Riel PLC; Wolbink G; van der Horst-Bruinsma IE; de Vries N; Tak PP; Ohmura K; Canhão H; Guchelaar HJ; Huizinga TW; Criswell LA; Raychaudhuri S; Weinblatt ME; Wilson AG; Mariette X; Isaacs JD; Morgan AW; Pitzalis C; Barton A; McKeigue P
    Ann Rheum Dis; 2019 Aug; 78(8):1055-1061. PubMed ID: 31036624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunological biomarker to predict MTX response in early RA.
    Ponchel F; Goëb V; Parmar R; El-Sherbiny Y; Boissinot M; El Jawhari J; Burska A; Vital EM; Harrison S; Conaghan PG; Hensor E; Emery P
    Ann Rheum Dis; 2014 Nov; 73(11):2047-53. PubMed ID: 23989988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study.
    Floris A; Perra D; Cangemi I; Congia M; Chessa E; Angioni MM; Mangoni AA; Erre GL; Mathieu A; Piga M; Cauli A
    Medicine (Baltimore); 2021 Apr; 100(17):e25481. PubMed ID: 33907096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.
    Emery P; Fleischmann RM; Hsia EC; Xu S; Zhou Y; Baker D
    Clin Rheumatol; 2014 Sep; 33(9):1239-46. PubMed ID: 25005327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
    Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
    J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients.
    Singh A; Gangadharan H; Gupta V; Patro PS; Misra R; Aggarwal A
    Int J Rheum Dis; 2021 May; 24(5):654-662. PubMed ID: 33780152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in IDO1
    Malik AE; Slauenwhite D; McAlpine SM; Hanly JG; Marshall JS; Issekutz TB
    Front Immunol; 2024; 15():1352251. PubMed ID: 38840915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.